DENVER, Colo., Sept 29, 2023 (www.247marketnews.com)- It was like this week shot out of a canon.
Monday
We started the week by covering Biophytis SA (NASDAQ: BPTS) and Skyepharma signing a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) to submit for marketing authorization applications. Biophytis was trading at $1.19, up $0.3009 (+35.21%), on 1.25M premarket shares traded when we covered it. It went on to open at $1.24, rode a wave to the $1.75 level, pulled back to around $1.50 and consolidated before running to its $2.06 high of the day, before pulling back to trade the last 5 hours near the $1.50 level and close at $1.59, up $0.7099 (+80.66%), on 66,419,997 shares traded.
TransCode Therapeutics (NASDAQ: RNAZ) announced that its lead therapeutic candidate, TTX-MC138, was delivered to brain tumors and effectively engaged its target in murine models bearing human glioblastoma multiforme (GBM) tumors, the most common and aggressive form of brain cancer, which we covered when it was trading at $0.81, up $0.146 (+21.68%), on 2.47M premarket shares traded.
We stated that “It looks like it wants to run to $1.50” and it did better than that. It opened at $1.31 and, despite a dozen trade halts, ran to a high of $3.20, then pulled back a little and mostly traded sideways to close at $2.55, up $1.886 (+284.04%), trading volume of 95,393,940 shares.
However, when the afterhours session closed, they dropped an anvil on the back of their shareholders’ heads by announcing that they closed a financing at 51 cents per share.
Next was Honeywell (NASDAQ: HON) and ESS Tech (NYSE: GWH) entering a strategic collaboration to advance technology development and market adoption of iron flow battery (IFB) energy storage systems, when ESS Tech was trading at $1.4701, up $0.0801 (+5.76%), on 220.8K premarket shares traded.
ESS Tech opened regular trading at $1.51, but couldn’t sustain any of its runs above $1.65, in the first half hour, and it retreated to around $1.52 for the next hour. It then spent the remainder of the session trading higher as it closed at $1.75, only a penny off of its high of the day, up $0.36 (+25.90%), on trading volume of 7,964,670 shares. The strong close signaled that it was still in play and it hit a high of $2.04 on Tuesday.
Tuesday
Tuesday was flat out amazing.
Despite getting a late start, we covered Immunovant (NASDAQ: IMVT) reporting that subcutaneously administered doses of IMVT-1402 achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, in initial data from a Phase 1 clinical trial in healthy adults, when it was trading at $29.02, up $8.28 (+43.09%), on 726.6K premarket shares traded. It gapped through its 52-week high to open at $32.29 and hit a high of $41.7199, before closing at $39.96, up $19.68 (+97.04%), on trading volume of 35,084,867 shares.
Then we covered Femasys (NASDAQ: FEMY) receiving 510(k) Clearance from the FDA for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube, when it was trading at $0.93, up $0.5984 (+180.66%), on 11.04M premarket shares traded. We stated that it looked ready to run and it didn’t disappoint, as it rode several waves higher and hit its $1.66 high about 15 minutes before it closed at $1.48, up $1.1484 (+346.32%), trading volume of 191,905,112 shares.
We covered BullFrog AI’s (NASDAQ: BFRG) positive preclinical data from a study investigating the anti-cancer activity assessing the relative efficacy of BF-222, when it was trading at $3.22, up $0.35 (+12.20%), on 1.58M premarket shares traded. it dropped to open at $3.12, but rallied to a high of $4.28 and closed at $3.55, up $0.68 (+23.69%), on 30,979,333 shares traded.
We originally were going to cover Soleno Therapeutics (NASDAQ: SLNO) when it was trading at $10.94, up $6.51 (+146.95%), on 3.4M, but had some other business to tend to and, by the time we were finally able to cover the Positive Top-line Results news, from its Study of C602 of DCCR for Prader-Willi Syndrome it was already at $18.54, up $14.11 (+318.51%), on 16.46M shares traded. no problem it hit a high of $30.30, before closing at $26.80, up $22.37 (+504.97%), on trading volume of 41,798,278 shares.
Wednesday
The day kicked off with Cardiff Oncology’s (NASDAQ: CRDF) positive clinical data with onvansertib monotherapy and combination therapy in ongoing metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC) trials, was a great way to start the day. We covered it when is trading at $1.88, up $0.26 (+16.05%), on 4.35M premarket shares traded and it hit $2.34 in the premarket, then topped out at our $2 next key inflection point.
ShiftPixy (NASDAQ: PIXY) stated that it would (1:24) reverse split the Company’s common stock on September 30, which we covered when it was trading at $0.741, up $0.306 (+70.39%), on 2.22M premarket shares traded.
It ran hard in the premarket to open the regular session at $1.32 and then hit a high of $1.38, twenty minutes later. It then retreated to around $1.10 and trade sideways for a couple of hours, when the bottom dropped out on its way to its low of $0.76, but it was able to rally and close at $1.05, up $0.615 (+141.38%), on trading volume of 154,549,923 shares.
SciSparc (NASDAQ; SPRC) was a second reverse share split news runner, which we covered when it was trading at $0.22, up $0.06 (+43.11%), on 4.58M premarket shares traded. It hit a $0.3657 high before closing at $0.2074, up $0.0513 (+32.86%), on 196,832,399 shares.
We then covered American Strategic Investment Co (NYSE: NYC) is trading at $7.81, up $1.59 (+25.56%), on 612.77K shares traded. Moments later it squeezed to 8.93, but that was short lived and it closed at $8.00, up $1.78 +28.62%, on 1,211,534 shares traded.
We covered Siyata Mobile (NASDAQ:SYTA) on Friday, when it was trading around $2 and it traded above $3 during the day. It’s since pulled back and may be consolidating in the upper twos and may still make another run to the $3.50 inflection point.
Immunovant (NASDAQ: IMVT) running to a new 52-week high of $44.19 was a nice bonus.
Thursday
Bionomics (NASDAQ: BNOX) reporting that its Phase 2b ATTUNE trial of BNC210 for the treatment of PTSD achieved positive topline results and met its primary endpoint was a great way to start the day and we covered the news when it was trading at $1.92, up $0.935 (+94.92%%), on 3.7M premarket shares traded.
It hit a premarket high of $7.84 and traded 35.7M premarket shares, then opened the regular session at $5.72, hit a high of $6.41, and closed at $3.37, up $2.385 (+242.13%), on trading volume of 125,838,813 shares.
Baudax Bio (NASDAQ: BXRX) stated that the FDA granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. It was trading at $0.46, up $0.16 (+52.00%), on 219.19K premarket shares traded, when we covered it. It opened at $0.5627, hit a high of $0.78, and closed at $0.452, up $0.152 (+50.67%), on 168.8M shares.
Friday
We decided to focus on Femasys (NASDAQ: FEMY) and reminded our readers that it was still in play, after publishing two announcements this week, when it was trading at $1.66, up $0.14 (+9.21%), on 445.35K premarket shares. We thought that it would hit a new 52-week high today and it delivered in spades, by hitting a $3.62 high, before closing at $2.98, up $1.46 (+96.05%), on trading volume of 158,753,867 shares.
Thank you for joining us this week. Have a great weekend and get ready for next Week!
Link to disclosure here.
